AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 22 min read$NGNE

Cvijic Christine Mikail sold $167K of NGNE

Cvijic Christine Mikail (President and CFO) sold 4,800 shares of Neurogene Inc. (NGNE) at an average of $34.71 ($34.06–$35.23, $0.17M total) across 3 trades over 2026-07-01 to 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cvijic Christine Mikail
Published Jul 2, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NGNE
Neutral
medium confidence
Mentioned
$NGNE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NGNENeutralLow
01

Why it matters

The disclosure updates the insider’s recent selling activity and may marginally influence near-term sentiment, but it does not change fundamentals or guidance in the text provided.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure limits interpretability as a bearish signal.

03

What to watch

The filing does not disclose any new operational/financial information; traders should avoid over-weighting insider sales when the plan is pre-arranged.

Relevance 3/10Novelty 5/10Timing: after-hours/filing update on 2026-07-02

Background

SEC Form 4 insider transaction for Neurogene Inc. (NGNE): President and CFO Cvijic Christine Mikail sold shares via open-market trades.

Company-level read

Ticker impact

$NGNENeutralMedium confidence
Context

Neurogene insider Form 4 shows CFO/President Cvijic sold 4,800 shares in open-market trades for ~$166.6K under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed insider sale with a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • company
    Neurogene Inc.

    Issuer of the Form 4 insider transaction; subject of the filing.

  • insider
    Cvijic Christine Mikail

    President and CFO; reported open-market sale of 4,800 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NGNE insider trading history →

Related articles

OCT 27
$NGNEMedAI 8/10

Neurogene presents preclinical data on Rett syndrome therapy

Neurogene Inc. (NGNE) presented preclinical data on its NGN-401 gene therapy for Rett syndrome, showing durable protein expression and clinical improvements in trials. The therapy has received multiple FDA designations. NGN-401 is being evaluated in the Embolden registrational clinical trial, with no procedure-related adverse events reported in Phase 1/2 trials.

investing.com2 min
OCT 27
$NGNEHighAI 8/10

Rett trial participants showed improvement at a median of two months. It continued through 30 months.

Neurogene (NGNE) presented preclinical and clinical data on NGN-401, a gene therapy for Rett syndrome. The data showed rapid and durable expression of MECP2 in all brain tissues, challenging prior assumptions about AAV delivery methods. Clinical improvements were observed at a median of two months, continuing through 30 months. The company also presented data supporting the use of ICV administration for broad CNS biodistribution.

stocktitan.net2 min
OCT 8
$NGNEHigh

JPMorgan says this biotech stock can more than double following steep declines

JPMorgan initiated coverage of Neurogene with an overweight rating and a $60 price target, implying 132% upside. The bank's optimism is based on the company's gene therapy for Rett syndrome. Neurogene shares have fallen 32% over the past three months, partly due to broader biotech sector declines and softer Q2 results. The company plans to release new trial data in 2027, which JPMorgan sees as a potential catalyst.

cnbc.com1 min
OCT 8
$NGNEHigh

JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

investing.com2 min
AUG 11
$NGNELow

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Inc. (NGNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participan

SEC EDGAR 8-K3 min